Biologics for Ulcerative Colitis May Decrease Risk for Advanced-Stage Cancer
Researchers sought to determine whether biologic treatment could affect the risk for advanced-stage inflammatory bowel disease-associated intestinal cancer.
Researchers sought to determine whether biologic treatment could affect the risk for advanced-stage inflammatory bowel disease-associated intestinal cancer.
Researchers compared proton pump inhibitors with histamine-2 receptor antagonists to determine if either treatment was associated with risk for IBD.
Researchers examined the relationship between antibiotic use and the development of inflammatory bowel disease in children.
Researchers evaluated the risk for Crohn disease, ulcerative colitis, and IBS in patients with acne starting isotretinoin treatment.
Researchers examined pain medication usage trends before and after initiating advanced therapy in patients newly diagnosed with inflammatory bowel disease.
The designation is supported by data from the 12-week, randomized, double-blind phase 2 FILLMORE trial.
The approval was based on data from a phase 1 study that compared the pharmacokinetics, safety, tolerability, and immunogenicity of Hadlima 100mg/mL to 50mg/mL.
Adam S. Faye, MD, discusses his team’s research on how antibiotics increase the risk for inflammatory bowel disease among older adults and what clinicians should keep in mind.
Researchers assessed whether rheumatoid arthritis is causally related to inflammatory bowel disease and vice versa.
Researchers examined the association between micronutrient intake and the risk for ulcerative colitis.